30 results about "Postoperative chemotherapy" patented technology

The invention belongs to the field of traditional Chinese medicine and relates to a traditional Chinese medicine compound preparation for treating ovarian cancer and a preparation method of the traditional Chinese medicine compound preparation. According to the traditional Chinese medicine compound preparation, extracts of bulk medicine such as astragalus mongholicus, codonopsis pilosula, rehmannia root, sculellaria barbata, asparagus cochinchinensis, medlar, cornu cervi, fiveleaf akebia fruit, elecampane and radix paeoniae alba are prepared into solid and liquid preparations. Animal experiment results show that the weight loss and the white cell reduction can be relieved, the T lymphocyte function is improved, the bax expression is increased, the cancer cell apoptosis is promoted, the anti-tumor angiogenesis effect is realized, the oxygen deficiency microenvironment of tumor cells is improved, and the sensitivity of ovarian cancer cells on chemotherapeutics is enhanced. Clinical test results show that the clinical symptoms of later-stage ovarian cancer patients can be relieved, and the survival quality of patients is improved; the chemotherapy toxic and side effect is lightened, and the chemotherapy tolerance and the compliance of the patients are improved; and the uncontrolled and recurrence rate of later-stage ovarian cancer can be reduced, and the five-year survival rate is improved; and no obvious adverse reaction exists, and good safety is realized. The traditional Chinese medicine compound preparation is applicable to the treatment on ovarian cancer and ovarian cancer postoperative chemotherapy patients.

The invention relates to a medical water-soluble cannabisdiol CBD preparation formula. The preparation is prepared from, by weight, 60-80 parts of water-soluble cannabisdiol CBD, 5-10 parts of water-soluble hypocannabidiol CBDa, 1-3 parts of and water-soluble cannabigerol CBG, 1-5 parts of water-soluble cannabis Elson CBE, 2-3 parts of water-soluble cannabis color CBC and 5-8 parts of water-soluble CBN. Compared with the prior art, the formula has the advantages that the water-soluble cannabisdiol CBD serves as the main component, does not contain addictive ingredients, has no psychoactive activity, does not produce dependence, and repairs cells and neuronal systems, and meanwhile the pharmacological action is achieved for resisting spasticity, anxiety, neurogenic diseases, pain and cancer; the preparation can be made to be effervescent tablets, dissolved medicines, capsules, soft capsules, tablets, sprays, emulsified oils, creams, transdermal patches, suppositories, expectorant tablets and sprays, the bioavailability is high, and the formula can play a good effect on cell repair of postoperative chemotherapy and radiotherapy for cancer and treatment of neuropathic diseases.

The invention discloses a medicine composition for nourishing spleen and kidney and building up healthful vital energy, which comprises functional ingredients and / or pharmaceutically acceptable carriers, wherein the functional ingredients are prepared by extracting codonopsis pilosula, radix astragali, barbary wolfberry fruit, Chinese angelica, glossy privet fruit, red-rooted salvia root, bighead atractylodes rhizome, south dodder seed, malaytea scurfpea fruit, poria cocos, white paeony root, coix seed, gardenia, and the like. The medicine composition has the efficacies of nourishing spleen and kidney and building up healthful vital energy, is applied for reducing the side reactions of patients with beast cancer caused by postoperative chemotherapy and radiotherapy, improving the immunologic function of a human body and is applied to the diseases caused by spleen and kidney weakness.

The invention discloses a medicament for treating colon cancer and a preparation method thereof. The medicament is prepared from medicinal active ingredients and pharmaceutic adjuvant, wherein the medicinal active ingredients comprise 3 beta-hydroxyl-28-deletion-12,17(18)-diene ursane. The preparation method comprises the following steps of: (1) adding methanol or ethanol into crushed charred sanguisorba root serving as a medicinal raw material, filtering the mixture, concentrating filtrate under normal pressure or reduced pressure to obtain extractum liquidum; (2) dispersing the extractum liquidum obtained by the step (1) with water, and extracting with chloroform to obtain extractum; (3) carrying out silicagel column chromatographic separation on the extractum obtained by the step (2) recovering a solvent, placing the solvent to separate white powder out, filtering the mixture to obtain the 3 beta-hydroxyl-28-deletion-12,17(18)-diene ursane; and (4) preparing the medicament from 20 to 90 weight percent of the 3 beta-hydroxyl-28-deletion-12,17(18)-diene ursane, and the balance of the pharmaceutic adjuvant by a conventional preparation method. The medicament mainly treats non-metastatic symptoms of the colon cancer, has no toxic or side effects, and is used by matching postoperative chemotherapy so as to relieve pain of patients.

The invention discloses a method for realizing chemosensitivity influence on laryngeal carcinoma cell lines by iron-carbon nanoparticle mediated cisplatin. The method comprises preparation of iron-carbon nanoparticles, loading of cisplatin by the iron-carbon nanoparticles as well as influence of iron-carbon nanoparticle mediated cisplatin on laryngeal carcinoma Hep-2 cell microstructure, proliferation activity as well as Survivin mRNA (messenger ribonucleic acid) and caspase3 mRNA expression. According to the invention, the magnetic nano material is adopted for the first time to load cisplatin, a chemotherapeutic drug with higher magnetism and targeting is provided, the preoperative chemotherapeutic effect on laryngeal carcinoma can be improved after the drug is applied to clinical practice, the necessary and efficient chemotherapeutic drug is provided for functional laryngeal carcinoma radical treatment is provided, and the drug can be applied to postoperative chemotherapy simultaneously; and toxic and side effects of the chemotherapeutic drug are reduced, the iron-carbon nano material has high drug loading capacity, stable release rate and higher targeting, and the iron-carbon nanoparticle mediated cisplatin can play an important role in clinical popularization and application for laryngeal carcinoma treatment.

The invention provides application of molecule miR-150 in screening preparation of a colorectal cancer detecting medicament. The molecule miR-150 is screened out by using a muParaflo microfluidic chip by the inventor of the invention; a paraffin section preparation of a clinical colorectal cancer patient is detected by an established digoxigenin labeled probe of miR-150 and an established detection method of qRT-PCR (Quantitative Real-Time-Polymerase Chain Reaction), respectively; results show that miR-150 low expression level in the clinical colorectal cancer patient indicates short lifetime of the patient and poor sensitivity of the patient to postoperative chemotherapy, and miR-150 high expression level indicates long lifetime of the patient and good sensitivity of the patient to postoperative chemotherapy. Compounds having high sensitivity to miR-150 can be screened by the method, and the compounds can be used for developing a kit for detecting the colorectal cancer. The kit is composed of compounds sensitive to the molecule miR-150 as active ingredients and a medicinal carrier. Simple detection of the miR-150 expression level is advantageous for monitoring of the colorectal cancer patient after healing and determination of chemotherapy sensitivity of the patient, and thus provides an effective method for clinical prevention and treatment of the colorectal cancer; high clinical application value and social benefit are created.

The invention discloses an application of m6A related lncRNA in preparation of a product for predicting colorectal cancer prognosis. According to the invention, lncRNAs related to m6A: AC087277.2, AC007991.4, AC008494.3, AC254629.1 and AL121583.1 are used as detection targets, and the constructed model is good in prediction performance; in clinical treatment, after patient diagnosis is clear, the constructed model can quickly judge the sensitivity of a high-risk early colorectal cancer patient to chemotherapy, a new treatment scheme is provided for postoperative chemotherapy of the early colorectal cancer patient, and important clinical significance and application prospects are achieved.

The invention discloses a medicine for alleviating postoperative chemotherapy-induced nausea and vomiting of a patient with an encephaloma and a preparation method. The medicine comprises the following raw materials: hyacinth bletilla, rhizoma zingiberis, cortex magnoliae officinalis, oxhide gelatin, liquorice, pig tripe, pig skin, semen strychni, valeriana officinalis, hindu datura flowers, eucommia, wild ginger, globose phaenosperma herb, silverweed cinquefoil roots, rabdosia amethystoides, radix morindae officinalis, rhizoma atractylodis, auriculate swallowwort roots, elecampane, katsumade galangal seeds, hindu lotus leaf-base, desmodium, fiveleaf akebia fruits, princesplume ladysthumb fruits, chirita fimbrisepala, ghostplant wormwood herb, false Chinese swertia herb, rust-coloured crotalaria herb with roots, ficus esquiroliana, astragalus smicus, fewflower wildrice fruits and ganoderma lucidum. The medicine has the beneficial effects that the medicine takes treatment principles of regulating a spleen, harmonizing a stomach, stopping vomiting, strengthening the spleen, replenishing qi, excreting dampness, protecting gastric mucosa and enhancing the immunity; a preparation process is simple; the curative effect is definite; the toxic and side effects are little; the dosing is convenient; the medicine is easy to prepare and low in cost; the possibility of relapse after treatment is low; the medicine property is specific; and the medicine can treat a specific disease rapidly and effectively.

The invention relates to the technical field of chemotherapy, in particular to a chemotherapy device used after liver cancer intervention, which comprises a mounting frame, an infusion mechanism, a shake reduction mechanism and a warning mechanism; a light-proof box is fixed in the water tank, the infusion mechanism is slidably mounted on the light-proof box, water is added into the water tank in the mounting frame, the sliding amplitude of the light-proof box is reduced, and a patient can conveniently move; a conical rod is arranged at the top of the light-proof box, a movable swing frame is slidably installed on the light-proof box, a containing cylinder is fixedly installed on the movable swing frame, and an electric heating wire is fixed to the outer portion of the containing cylinder; the infusion mechanism is used for keeping chemotherapeutics away from light, so that the efficacy of the chemotherapeutics is ensured; an infusion bottle in the containing cylinder is heated by the electric heating wire, so that liquid in the infusion bottle reaches the most comfortable temperature of a patient; when the patient moves, the shake reduction mechanism reduces the shake amplitude of an infusion tube and prevents an infusion needle from shaking when the infusion tube shakes; and the warning mechanism provides replacement signals for medical staff and the patient, and blood return of the patient after liquid infusion is prevented.

The invention discloses the application of HDS in predicting the prognosis of gastric cancer patients, guiding postoperative adjuvant chemotherapy and predicting the curative effect of immunotherapy. The present invention screens and obtains 103 genes related to the prognosis of gastric cancer, constructs the HDS score based on the PCA method, and the analysis results prove that the gastric cancer patients in the high HDS group have a longer survival time than the low HDS group; gastric cancer patients with high HDS are more suitable for the use of immune Treatment; patients with stage II low-HDS gastric cancer benefited more from postoperative chemotherapy than those with high-HDS gastric cancer. The HDS evaluation system of the present invention provides a new method for predicting the prognosis of gastric cancer and selecting postoperative adjuvant chemotherapy and immunotherapy, and has good clinical application prospects.

The invention discloses a medicament for treating breast cancer and a preparation method thereof. The medicament comprises a preparation which is prepared from 3-beta-oxygen-alpha-L-arabinofuranosyl-based-28-norepinephrine ursolic-12, 17-diene serving as a medicinal active ingredient and medicinal auxiliary materials. The medicament comprises 1 to 90 weight percent of the medicinal active ingredient and 10 to 99 weight percent of the medicinal auxiliary materials. The medicinal active ingredient has a structural formula shown in the specification. The preparation method for the medicament fortreating the breast cancer comprises the following steps of: (1) crushing sanguisorba carbon serving as a medicinal raw material; extracting and filtering repeatedly; and concentrating filtrate to obtain a liquid extract; (2) dispersing the liquid extract obtained in the step (1) with water; extracting the dispersed liquid extract with chloroform; and recovering a solvent from extract liquid under normal pressure or a reduced pressure to obtain an extract; (3) performing silica column chromatography separation on the extract obtained in the step (2); performing recrystallization on solid obtained by suction filtering to obtain the medicinal active ingredient of a compound; and (4) preparing the preparation by using 20 to 90 weight percent of the medicinal active ingredient and the balanceof the medicinal auxiliary materials. The medicament is used for treating the breast cancer, has a good treatment effect, and can replace oral Western medicament in a postoperative chemotherapy period.

The invention discloses a traditional Chinese medicine capsule for replacing cancer postoperative chemotherapy. The invention relates to an anti-cancer traditional Chinese medicine capsule capable of clearing away heat and toxic materials and reducing or replacing the postoperative chemotherapy course of a cancer patient. The anti-cancer traditional Chinese medicine capsule is prepared from 15%-15.5% of taxus chinensis seeds, 7.5%-7.75% of stichopus japonicus, 7.5%-7.75% of paris polyphylla, 7.5%-7.75% of semen strychni, 7.5%-7.75% of oldenlandia diffusa, 7.5%-7.75% of pangolin scales, 7.5%-7.75% of gecko, 7.5%-7.75% of scorpio, 7.5%-7.75% of centipede, 15%-15.5% of dandelion and 7.5%-7.75% of liquorice. The traditional Chinese medicine composition has the advantages that malignant tumor development can be inhibited in a mode of combating poison with poison, the effect of replacing postoperative chemotherapy is achieved, the immunity of a patient can be improved by curing cancerous cells, and then cancer cells are inhibited and cured by relying on the immunity of the patient.

The invention discloses a use of cedar acid in reversing paclitaxel medical resistance in ovarian cancer. Ovarian cancer is one of the three major malignant tumors of female reproductive system, and the survival time of most patients with advanced ovarian cancer is less than 5 years. Clinical treatment of ovarian cancer usually uses cytoreductive surgery and postoperative chemotherapy with platinum and paclitaxel. However, ovarian cancer cell resistance to chemotherapy drugs leads to high recurrence rate and mortality, so it becomes the bottleneck of clinical treatment. The invention disclosesthat yew antler acid, yew antler alkyd and cedric acid can enhance the proliferation inhibition effect of Taxol on A2780 / Taxol cells in different degrees, improve the sensitivity of cells to Taxol, and can be developed as a medicine for reversing the resistance of ovarian cancer to taxol. The use is characterized in that the yew antler acid, yew antler alkyd and cedric acid can enhance the proliferation inhibition effect of Taxol on A2780 / Taxol cells in different degrees and improve the sensitivity of cells to Taxol.

The invention discloses a medicinal composition with effects of improving the immunity of organisms and liver functions. The medicinal composition consists of Chinese caterpillar fungus, bear gall, Chinese wolfberry, donkey-hide glue, virgate wormwood herb, villous amomum fruit, pangolin scales and golden hair grass. The medicinal composition is prepared into clinically-acceptable honeyed paste, tablets, capsules, granules, pills, powder or oral liquid by adding the conventional auxiliary materials according to the conventional process. The medicinal composition can improve the immunity of the organisms and the liver functions, and has the obvious effect on postoperative chemotherapeutic patients or patients in poor health.

The invention provides a traditional Chinese medicine preparation used for treating ovarian cancer. The traditional Chinese medicine preparation is prepared from the following bulk drugs, by weight: 8-10 parts of nux vomica, 10-15 parts of Herba Patriniae, 10-20 parts of hedyotis, 12-16 parts of Rhizoma Drynariae, 14-20 parts of Caulis Spatholobi, 20-25 parts of Sagina japonica, 15-20 parts of Cortex Cinnamomi, 20-25 parts of Sichuan lovage rhizome, 20-30 parts of Semen Persicae, 10- 15 parts of Rhizoma Zingiberis, 30-40 parts of liquorice roots, and 30-40 parts of Fructus Crataegi. The preparation is capable of suppressing tumor cells, reinforcing the vital essence and strengthening the primordial qi, boosting immunity of patients, reducing pain of patients, improving life quality of patients and prolonging survival time of patients, and is low in side effect, simple to prepare and convenient to take. Raw materials are easily available, the price is low, and the traditional Chinese medicine preparation is suitable for long-term taking of patients. Patients with advanced ovarian cancer who have relapsed after postoperation chemotherapy, or who cannot tolerate chemotherapy, or who lose the chance of surgery, or who cannot tolerate surgery due to poor physical condition, can be treated by adopting the traditional Chinese medicine preparation.

The invention relates to application of chemotherapy-related gene expression characteristics in prediction of pancreatic cancer prognosis, and belongs to the technical field of biological medicines. According to the application of chemotherapy-related gene expression characteristics in prediction of pancreatic cancer chemotherapy response, immune cell infiltration and prediction models, the gene expression levels of BCHE, ADH1A and TSN4 in postoperative tumor tissues of pancreatic cancer patients are detected; related gene expression characteristic scores are calculated as objective indexes to reflect pancreatic cancer chemotherapy drug sensitivity, tumor purity, tumor immune cell infiltration level and potential tumor biological behaviors, and are used for guiding postoperative chemotherapy and immunotherapy of pancreatic cancer patients and promoting individualized treatment of pancreatic cancer; and meanwhile, pancreatic cancer prognosis risk layering is carried out based on chemotherapy-related gene expression characteristics, better prediction efficiency is achieved, the pancreatic cancer patients can obtain more clinical net income, and the application is applied to accurate clinical judgment of the postoperative survival time of the pancreatic cancer patients.

The invention discloses a preparation method of an assisted drug for postoperative chemo-treatment of non-small cell lung cancer and solves the problem of treatment of postoperative chemo-treatment. The preparation method is characterized by comprising the following steps: 1, extracting volatile oil from groundsel, grassleaf sweelflag rhizome and fleece-flower root crude powder for standby use; 2, smashing honey locust into fine powder for standby; 3, performing water-extraction to elsholtzia rugulosa, leaves of tomentosecalyx elsholtzia, Leycesteria formosa Wall, fermented pinellia (wrapped during decocting), red clover, cassia twig and herb residue obtained in step 1, and obtaining primary material through concentrating under reduced pressure and drying; 4, spraying the volatile oil into the primary material, adding the honey locust fine powder, well mixing, sieving with a 60-mesh screen, and placing the product into capsules to obtain the assisted drug. Clinical trial proves that the assisted drug has good effect and relatively high security in chemo-treatment and synergism and is worthy of clinical application and popularization.

The invention belongs to the field of traditional Chinese medicine and relates to a traditional Chinese medicine compound preparation for treating ovarian cancer and a preparation method of the traditional Chinese medicine compound preparation. According to the traditional Chinese medicine compound preparation, extracts of bulk medicine such as astragalus mongholicus, codonopsis pilosula, rehmannia root, sculellaria barbata, asparagus cochinchinensis, medlar, cornu cervi, fiveleaf akebia fruit, elecampane and radix paeoniae alba are prepared into solid and liquid preparations. Animal experiment results show that the weight loss and the white cell reduction can be relieved, the T lymphocyte function is improved, the bax expression is increased, the cancer cell apoptosis is promoted, the anti-tumor angiogenesis effect is realized, the oxygen deficiency microenvironment of tumor cells is improved, and the sensitivity of ovarian cancer cells on chemotherapeutics is enhanced. Clinical test results show that the clinical symptoms of later-stage ovarian cancer patients can be relieved, and the survival quality of patients is improved; the chemotherapy toxic and side effect is lightened, and the chemotherapy tolerance and the compliance of the patients are improved; and the uncontrolled and recurrence rate of later-stage ovarian cancer can be reduced, and the five-year survival rate is improved; and no obvious adverse reaction exists, and good safety is realized. The traditional Chinese medicine compound preparation is applicable to the treatment on ovarian cancer and ovarian cancer postoperative chemotherapy patients.

The invention discloses a postoperative traditional Chinese medicine for treatment of breast cancer and a preparation method thereof. The postoperative traditional Chinese medicine includes followingcomponents: 10 to 15% of Oldenlandia diffusa, 8 to 12% of Astragalus membranaceus, 5 to 10% of bighead atractylodes rhizome, 5 to 10% of licorice, 10 to 15% of turtle shell, 8 to 12% of radices trichosanthis, 8-12% of edible tulip, 5-10% of Antenoron filiforme, 3-12% of Rhizoma Curcumae, 6-12% of semen trichosanthis and 8 to 12% of root of common peony. The postoperative traditional Chinese medicine for treatment of breast cancer mainly plays the role of killing cancer cells after operation, and alleviates the pain of postoperative chemotherapy for breast cancer patients.

The invention discloses a medicament for treating breast cancer and a preparation method thereof. The medicament comprises a preparation which is prepared from 3-beta-oxygen-alpha-L-arabinofuranosyl-based-28-norepinephrine ursolic-12, 17-diene serving as a medicinal active ingredient and medicinal auxiliary materials. The medicament comprises 1 to 90 weight percent of the medicinal active ingredient and 10 to 99 weight percent of the medicinal auxiliary materials. The medicinal active ingredient has a structural formula shown in the specification. The preparation method for the medicament for treating the breast cancer comprises the following steps of: (1) crushing sanguisorba carbon serving as a medicinal raw material; extracting and filtering repeatedly; and concentrating filtrate to obtain a liquid extract; (2) dispersing the liquid extract obtained in the step (1) with water; extracting the dispersed liquid extract with chloroform; and recovering a solvent from extract liquid under normal pressure or a reduced pressure to obtain an extract; (3) performing silica column chromatography separation on the extract obtained in the step (2); performing recrystallization on solid obtained by suction filtering to obtain the medicinal active ingredient of a compound; and (4) preparing the preparation by using 20 to 90 weight percent of the medicinal active ingredient and the balance of the medicinal auxiliary materials. The medicament is used for treating the breast cancer, has a good treatment effect, and can replace oral Western medicament in a postoperative chemotherapy period.

The invention discloses use of lacca acid in reversing paclitaxel medical resistance in ovarian cancer. Ovarian cancer is one of the three major malignant tumors of female reproductive system, and thesurvival time of most patients with advanced ovarian cancer is less than 5 years. Clinical treatment of ovarian cancer usually uses cytoreductive surgery and postoperative chemotherapy with platinumand paclitaxel. However, ovarian cancer cell resistance to chemotherapy drugs leads to high recurrence rate and mortality, so it becomes the bottleneck of clinical treatment. The invention discloses that lacca acid, lacca acid alkyd and cedric acid can enhance the proliferation inhibition effect of Taxol on A2780 / Taxol cells in different degrees, improve the sensitivity of cells to Taxol, and canbe developed as a medicine for reversing the resistance of ovarian cancer to taxol. The invention is characterized in that the lacca acid, lacca acid alkyd and cedric acid can enhance the proliferation inhibition effect of Taxol on A2780 / Taxol cells in different degrees and improve the sensitivity of cells to Taxol.

The invention discloses a medicament for treating breast cancer and a preparation method thereof. The medicament comprises medicament effective components which are 3beta-hydroxyl-28- norursol-12 and 17-diene-22-ketone and a medicament which is prepared from a medicinal auxiliary material, wherein the medicament effective components are 1-90 percent by weight, and the medicinal auxiliary materialis 10-99 percent. The structural formula of the medicament effective components is shown in the specification. The preparation method comprises the following steps of: (1) pulverizing garden burnet carbon as a medicament raw material, adding carbinol or ethanol, extracting and filtering and concentrating filter liquor to obtain fluid extract; (2) dispersing the fluid extract in the step (1) by water, extracting by chloroform and recovering a solvent of extract liquor to obtain extract; (3) carrying out silica gel column chromatography separation on the extract in the step (2) and sucking and filtering the obtained solid and recrystallizing to obtain the medicament effective components of the compound; and (4) taking the medicament effective components according to the weight proportion and retaining the medicinal auxiliary material for preparing the medicament. The invention has good treatment effect on treating breast cancer and can replace western medicines for oral administration in the postoperative chemotherapy period.

The invention belongs to the technical field of clinical tumor diagnosis, and particularly relates to a model and a prediction kit for predicting whether cerebrospinal fluid peptide fragments of a patient suffering from myeloblastoma are transferred or not in the future according to the change of the components of the cerebrospinal fluid peptide fragments. The method is applied to prediction of myeloblastoma metastasis, the sensitivity of the method is 70.8%, the specificity of the method is 100%, and the AUC value of the method is 0.9619. The method not only can guide tumor staging, but alsocan adjust the postoperative chemotherapy dosage according to the patient metastasis possibility and improve the patient prognosis. And a basis is provided for searching a sensitive and specific medulloblastoma cerebrospinal fluid marker.

The invention discloses a use of yew antler alkyd for reversing ovarian cancer resistance to paclitaxel. Ovarian cancer is one of the three major malignant tumors of female reproductive system, and the survival time of most patients with advanced ovarian cancer is less than 5 years. Clinical treatment of ovarian cancer usually uses cytoreductive surgery and follows by postoperative chemotherapy with platinum and paclitaxel. However, ovarian cancer cell resistance to chemotherapy drugs leads to high recurrence rate and mortality, so it becomes the bottleneck of clinical treatment. The inventiondiscloses that yew antler acid, yew antler alkyd and cedric acid can enhance the proliferation inhibition effect of Taxol on A2780 / Taxol cells in different degrees, improve the sensitivity of cells to Taxol, and can be developed as a medicine for reversing the resistance of ovarian cancer to taxol.

The invention discloses a medicament for treating breast cancer and a preparation method thereof. The medicament comprises medicament effective components which are 3beta-hydroxyl-28- norursol-12 and 17-diene-22-ketone and a medicament which is prepared from a medicinal auxiliary material, wherein the medicament effective components are 1-90 percent by weight, and the medicinal auxiliary material is 10-99 percent. The structural formula of the medicament effective components is shown in the specification. The preparation method comprises the following steps of: (1) pulverizing garden burnet carbon as a medicament raw material, adding carbinol or ethanol, extracting and filtering and concentrating filter liquor to obtain fluid extract; (2) dispersing the fluid extract in the step (1) by water, extracting by chloroform and recovering a solvent of extract liquor to obtain extract; (3) carrying out silica gel column chromatography separation on the extract in the step (2) and sucking and filtering the obtained solid and recrystallizing to obtain the medicament effective components of the compound; and (4) taking the medicament effective components according to the weight proportion and retaining the medicinal auxiliary material for preparing the medicament. The invention has good treatment effect on treating breast cancer and can replace western medicines for oral administration in the postoperative chemotherapy period.

The invention discloses application of HDS in predicting prognosis of gastric cancer patients, guiding postoperative adjuvant chemotherapy and predicting the curative effect of immunotherapy. 103 genes related to gastric cancer prognosis are obtained through screening, an HDS score is constructed based on a PCA method, and analysis results prove that gastric cancer patients in a high HDS group have longer survival time than gastric cancer patients in a low HDS group; high-HDS gastric cancer patients are more suitable for immunotherapy; and patients with stage II low-HDS gastric cancer gain more benefits from postoperative chemotherapy than patients with high-HDS gastric cancer. The HDS evaluation system provides a new method for predicting prognosis of gastric cancer and selecting postoperative adjuvant chemotherapy regimens and immunotherapy regimens, and has a good clinical application prospect.

Ruxiankang oral liquid is medicine which is prepared by, by weight, 1-10 parts of cantharides, 1-10 parts of centipede, 5-15 parts of scorpion, 1-10 parts of snake slough, 5-15 parts of cicada slough, 1-10 parts of garter snake, 5-15 parts of huechys, 5-15 parts of ground beetle, 5-15 parts of earthworm, 5-15 parts of ginseng, 5-15 parts of rhubarb, 5-15 parts of radix aucklandiae, 5-15 parts of leech, 5-15 parts of cowherb seed, 800-1300 parts of water and 1200-1700 parts of wine according to a conventional preparation method. The Ruxiankang oral liquid has the advantages that the oral liquid is natural medicine for treating breast diseases such as female breast cancer and breast hyperplasia, operative treatment can be avoided, patients are freed from pain and side effects of postoperative chemotherapy and radiation therapy, the oral liquid is quite evident in curative effect and fills up the blank for using medicine to treat the breast diseases, the effective rate of the oral liquid reaches 95.5%, the marked effective rate of the oral liquid reaches 91%, and the cure rate of the oral liquid reaches 86.5%.

The invention discloses a use of yew antler alkyd for reversing ovarian cancer resistance to paclitaxel. Ovarian cancer is one of the three major malignant tumors of female reproductive system, and the survival time of most patients with advanced ovarian cancer is less than 5 years. Clinical treatment of ovarian cancer usually uses cytoreductive surgery and follows by postoperative chemotherapy with platinum and paclitaxel. However, ovarian cancer cell resistance to chemotherapy drugs leads to high recurrence rate and mortality, so it becomes the bottleneck of clinical treatment. The inventiondiscloses that yew antler acid, yew antler alkyd and cedric acid can enhance the proliferation inhibition effect of Taxol on A2780 / Taxol cells in different degrees, improve the sensitivity of cells to Taxol, and can be developed as a medicine for reversing the resistance of ovarian cancer to taxol.